Role of Smooth Muscle Cells in the Initiation and Early Progression of Atherosclerosis | Arteriosclerosis, Thrombosis, and...
Specific regions of the vascular tree are more susceptible to the development of atherosclerosis than others, and these regions are found to have abundant SMCs in the intima. In vitro mechanistic and in vivo correlative data provide evidence that these phenotypically modulated SMCs participate in functions that can lead to atherogenesis as outlined above. While these data suggest a key role for SMCs in the initiation and early progression of atherosclerosis, mechanistic in vivo data confirming the role of SMCs in these processes are just recently surfacing. These studies have been hindered by the fact that lesions are complex and many SMC functions that would lead to atherosclerosis initiation and progression are redundant with other cell types that participate in early lesion development. More definitive studies involving the depletion of a specific cell type, as has been done with specific inflammatory cell populations to confirm their role in atherosclerosis, are not ...http://atvb.ahajournals.org/content/28/5/812
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy - Full...
This is a single-arm, open-label study, meaning all patients will be treated in the same fashion with the investigational agent. Scans will be performed every 3 cycles of treatment, and patients will be withdrawn from study in the event of progression or drug intolerance as defined within the protocol.. Treatment will be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's malignancy.. The length of each cycle is 21 days. For the first cycle of treatment, cabazitaxel will be dosed at 20 mg/m2. During cycle 1, complete blood counts will be performed on days 8 and 15, and dosing on Day 1 cycle 2 will depend upon the nadir counts on those days. If, on toxicity assessment on day 1 of cycle 2, the patient has no residual ,grade 2 toxicity, and all other laboratory parameters are within acceptable limits (see below),at the investigator's discretion the dose can be ...https://clinicaltrials.gov/ct2/show/NCT01437488
Abstract 6011: Impact Of Atherosclerotic Disease Progression On Mid-term Clinical Outcome In Diabetic Patients In The Drug...
Drug-eluting stents (DES) implantation has been demonstrated to dramatically reduce restenosis and repeat revascularisation (RR) in diabetic patients. However, diabetic patients are prone to an accelerated atherosclerotic process and the impact of atherosclerotic disease progression (ADP) on RR and mid-term clinical outcome after DES implantation is not well known To determine whether RR in diabetic patients treated with prior DES is the result of either DES restenosis or native progression of atherosclerotic disease in the coronary vasculature, and to evaluate the impact of ADP on the mid-term clinical outcome. We followed 316 consecutive diabetic patients (227 men, age 69 ± 9 years) treated between June 2005 and September 2006 with at least one DES. Of these patients, 260 (82%) had a multivessel coronary disease, 148 (41%) had previous coronary revascularisation and 104 (32%) had insulin-dependent diabetes. During the ...http://circ.ahajournals.org/content/118/Suppl_18/S_1046.2
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following...
The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK)http://adisinsight.springer.com/trials/700261097?error=cookies_not_supported&code=37090fd4-d9e0-4856-9136-743d340ff491
Most recent papers with the keyword Her2 colon | Read by QxMD
HER2 gene amplifications and activating mutations in the HER2 receptor tyrosine kinase are present in 4% of metastatic colorectal cancers (mCRCs). HER2-targeted therapy is not standard of care, although preclinical and clinical data suggest that patients with HER2 amplifications and/or HER2-activating mutations may benefit from HER2-directed therapy. HER2 amplifications and activating mutations have also been implicated in resistance to anti-epidermal growth factor receptor-based therapy. This report describes a patient with KRAS, NRAS, and BRAF wild-type mCRC who experienced disease progression on first-line treatment with FOLFIRI and cetuximab after only 5 months, and subsequently experienced progression on second-line treatment with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline ...https://www.readbyqxmd.com/keyword/72720
An Open-Label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-Based...
This single arm study will assess the safety and efficacy of a regimen of Avastin plus a taxane, with or without additional chemotherapy, as first-linehttp://adisinsight.springer.com/trials/700022954?error=cookies_not_supported&code=94e1dd33-70d8-4d84-b82c-6a24cb2c41f4
Predictors of disease progression in HIV infection: a review | AIDS Research and Therapy | Full Text
The value of HIV-RNA quantification as a prognostic marker has long been established [6, 51, 52]. An approximately inverse relationship to the CD4+ T-cell count and survival time has been observed in around 80% of patients [53, 54]. Higher HIV-RNA levels are associated with more rapid decline of CD4+ T-cells, assisting prediction of the rate of CD4 count decline and disease progression. However, once the CD4 count is very low (,50-100 cells/mm3), the disease progression risk is so great that HIV-RNA levels add little prognostic information [25, 54-56]. The correlation between CD4 count and disease progression seen clearly in Table 1 has already been described . Further highlighting the risk of AIDS in those with CD4 counts of 200-350 cell/mm3 (the current threshold for ART initiation), a four-fold risk increase can be seen between those with a HIV-RNA of 3000 copies/mL and those with ≥300 000 copies/mL, ...https://aidsrestherapy.biomedcentral.com/articles/10.1186/1742-6405-4-11
Prevention of Kidney Disease Progression
This page includes the following topics and synonyms: Prevention of Kidney Disease Progression, Chronic Kidney Disease Prevention.http://www.fpnotebook.com/legacy/Renal/Prevent/PrvntnOfKdnyDsPrgrsn.htm
Combination Therapy Delays Disease Progression in Advanced Pancreatic Cancer | Medpage Today
MILAN, Italy-A four-drug chemotherapy cocktail prolongs progression-free survival in patients with advanced pancreatic cancer, according to a study published online by The Lancet Oncology.https://www.medpagetoday.com/gastroenterology/pancreaticdiseases/1014
Prostate Cancer Progression Risk in AS Not Linked to Family History - Renal and Urology News
A family history of prostate cancer was not a major determinant of disease progression during active surveillance, according to a systematic review.http://www.renalandurologynews.com/prostate-cancer/prostate-cancer-family-history-not-important-active-surveillance-criteria/article/649083/
Metabolic Syndrome, Diabetes, and Incidence and Progression of Coronary Calcium | JACC: Cardiovascular Imaging
In the MESA, persons with MetS or DM have a greater incidence and progression of CAC than those subjects without MetS, and those with MetS (without DM) have an intermediate incidence and progression. Also, insulin resistance (23) and DM (24,25) have been shown in smaller or selected cohorts to relate to progression of CAC, and in those with DM, a glycated hemoglobin ≥7% predicted progression of CAC (26). Progression of CAC has also been shown to predict total mortality over baseline risk factors and CAC (13). In our study, we also found increased progression of CAC in persons with MetS and DM to predict future CHD events.. The baseline calcium score, a strong predictor of CAC progression, is important to understanding the relationship of MetS and DM to progression of CAC (23,27). Because MetS is associated with an intermediate level and DM the highest level of CAC, we might ...http://imaging.onlinejacc.org/content/5/4/358
Disease progression | Article about disease progression by The Free Dictionary
Looking for disease progression? Find out information about disease progression. impairment of the normal state or functioning of the body as a whole or of any of its parts. Some diseases are acute, producing severe symptoms that... Explanation of disease progressionhttp://encyclopedia2.thefreedictionary.com/disease+progression
Researchers discover role of microglia during early progression of Alzheimer's disease
For the first time, researchers have determined how toxic tau fibrils spread by the help of brain immune cells called microglia during the early stages of Alzheimer's disease (AD). The discovery of this new pathway may lead ...https://medicalxpress.com/news/2015-10-role-microglia-early-alzheimer-disease.html
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov
Duration of response is defined for all evaluable patients with measurable disease who have achieved a confirmed response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented. If a patient dies subsequent to the confirmed response without a documentation of disease progression, the patient will be considered to have had disease progression at the time of their death. In the case of a patient failing to return for evaluations before a documentation of disease progression, the patient will be censored for progression on the date of last evaluation. The distribution of duration of response will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% ...https://clinicaltrials.gov/ct2/show/NCT00423917
Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility | SpringerLink
In this study, we aimed to characterise rapid progressors to type 1 diabetes among children recruited from the general population, on the basis of HLA-conferred disease susceptibility. We monitored 74https://link.springer.com/article/10.1007/s00125-017-4258-7
Abemaciclib Approved by FDA for Use in HR+/HER2- Breast Cancer
Abemaciclib (Verzenio) has been approved by the FDA for use as a monotherapy and in a combination regimen for patients with HR-positive/HER2-negative breast cancer. As a monotherapy, the CDK4/6 inhibitor has been approved for patients with metastatic disease who have previously received endocrine therapy and chemotherapy, and as a combination, abemaciclib has been approved for use with fulvestrant for women with advanced breast cancer with disease progression following endocrine therapy.http://www.targetedonc.com/news/abemaciclib-approved-by-fda-for-use-in-hrher2-breast-cancer
ORBi: Browsing ORBi
in PLoS ONE (2011), 6(11), 26450. Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is ... [more ▼]. Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is not known. We investigated the effect of this protease on cell migration and angiogenesis in vitro and studied the expression of meprin-α mRNA, protein and proteolytic activity in primary tumors at progressive stages and in liver metastases of patients with colorectal cancer, as well as inhibitory activity towards meprin-α in sera of cancer patient as compared to healthy controls. We found that the hepatocyte growth factor (HGF)- induced migratory response of meprin-transfected epithelial cells was increased compared to ...http://orbi.ulg.ac.be/browse?type=title&sort_by=2&order=ASC&rpp=20&etal=3&offset=49140
progression - Symptoms, Treatments and Resources for progression
progression - MedHelp's progression Center for Information, Symptoms, Resources, Treatments and Tools for progression. Find progression information, treatments for progression and progression symptoms.http://www.medhelp.org/tags/show/61227/progression
Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial...
Netea, M.G. ; Hijmans, A.; Wissen, S. van; Smilde, T.J. ; Trip, M.D.; Kullberg, B.J. ; Boo, T. de; Meer, J.W.M. van der ; Kastelein, J.J.P.; Stalenhorf, A.F.H. ...http://repository.ubn.ru.nl/handle/2066/13834
Download free AIDS - Initial Theories and Disease Progression News Widget | Medindia
Free AIDS - Initial Theories and Disease Progression News Widget easy download for websites. Regularly updated dynamic AIDS - Initial Theories and Disease Progression news content.http://www.medindia.net/free-downloads/news-widget/AIDS-Initial-Theories-Disease-Progression-news-widget.asp
Global Biomarkers Market Estimated to Grow Strongly by 2020 - PMR Study Report | Medgadget
Biomarkers are used to detect, predict disease susceptibility and monitor disease progression for infectious diseases, cancer, metabolic diseases, centralhttps://www.medgadget.com/2017/01/global-biomarkers-market-estimated-to-grow-strongly-by-2020-pmr-study-report.html
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth - Full Text...
Numerous studies have demonstrated an association between HLA class I genotypes with differing progression to AIDS in individuals who are followed after being off antiretroviral therapy. These studies do not always associate the same HLA class I alleles with the risks of HIV-1 disease progression; however they consistently demonstrated that HLA-B*35 and B*53 portend a bad outcome compared to the better outcome observed in HLA-B*27 and B*57 carriers. Despite this information, very little data exists to explain the mechanism of this association.. This longitudinal study will look at the HIV-1 specific CD8+ T-cell responses and the dominant HIV-1 genotype among individuals identified as HLA-B*27, B*35, B*53 and B*57 positive through studies done in collaboration with the REACH project. ...https://clinicaltrials.gov/ct2/show/NCT00107029
A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3...
There is substantial evidence that rIL-2 increases CD4+ cell count. Whether or not rIL-2 delays progression to AIDS and extends survival is currently unknown, such clinical benefits of rIL-2 can only be established in a large, long-term, randomized trial. This study examines the effect of two different rIL-2 doses on HIV viral burden and CD4+ cell count and provides additional information on optimal dosing, safety, and antiviral activity of rIL-2.. Patients are randomized to receive one of two subcutaneous (sc) doses of recombinant rIL-2 or no rIL-2. Those patients who take rIL-2 initially receive three courses of treatment. For this study, a course is defined as eight calendar weeks, including the five-day period of sc rIL-2 administration. Additional courses are given (no more frequently than every 6 weeks) in order to maintain a CD4+ count of at least twice its baseline level or at least 1,000 cells/mm3. Follow-up will continue for all patients until a common closing date of 12 months ...https://clinicaltrials.gov/show/NCT00000949?order=666
Examining how psychiatric disorders progress
Loyola Medicine psychiatrist Angelos Halaris, MD, is co-editor of a major new publication examining how psychiatric disorders progress over time, and how this progression can be stopped.https://medicalxpress.com/news/2017-09-psychiatric-disorders.html
868 The analysis of gene expression patterns during tumor development may provide valuable information that will lead to the identification of potential signaling pathways suitable for chemoprevention and/or chemotherapeutic intervention. Several challenges exist, however, in the use of human tissues for the analysis of molecular changes associated with tumor development, including the ability to obtain equivalent non-diseased human tissue for laboratory analyses. In contrast, tissues can be obtained readily from genetically related affected and unaffected animals. Therefore, animal models are ideal for comparing gene expression patterns of normal and tumor tissue. The goal of the present study is to examine gene expression patterns in the OH-BBN-induced bladder cancer model in Fischer 344 rats. Chemically induced rat models such as this one exist for various cancers and parallel the molecular and/or histopathological changes that occur in humans during the early and progressive stages of ...http://cancerres.aacrjournals.org/content/66/8_Supplement/205.1